NTCP Inhibitors
The chemical class identified as NTCP inhibitors encompasses a wide array of compounds designed to either directly target the Na+/taurocholate cotransporting polypeptide (NTCP) or modulate its activity indirectly through various pathways. Myrcludex-B emerges as a noteworthy direct NTCP inhibitor, strategically crafted to impede viral entry into hepatocytes, showcasing its potential as an antiviral agent. On the other hand, Ezetimibe, Cyclosporin A, Bosentan, Rosuvastatin, Rifampicin, Irbesartan, Pravastatin, Telmisartan, Enalapril, Gemfibrozil, and Naringenin act as indirect NTCP inhibitors, impacting NTCP activity through diverse mechanisms. Myrcludex-B, as a direct NTCP inhibitor, specifically focuses on preventing viral entry into hepatocytes.
In contrast, the indirect NTCP inhibitors in this chemical class exert their effects through modulating various pathways related to NTCP activity. Ezetimibe, for instance, influences cholesterol metabolism, impacting NTCP indirectly. This cholesterol-lowering agent showcases the intricate interplay between lipid metabolism and NTCP function. Similarly, Cyclosporin A and Bosentan, known for their immunosuppressive and endothelin receptor antagonist properties, respectively, indirectly modulate NTCP activity, likely through pathways beyond their primary indications. Statins, including Rosuvastatin and Pravastatin, contribute to indirect NTCP inhibition by reducing cholesterol levels. Their impact on cholesterol metabolism extends to influencing NTCP activation, offering a nuanced approach to hepatic transport modulation. Rifampicin, a well-known inducer of CYP3A4, stimulates bile acid synthesis, indirectly influencing NTCP expression.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ezetimibe | 163222-33-1 | sc-205690 sc-205690A | 25 mg 100 mg | $96.00 $241.00 | 12 | |
Ezetimibe indirectly inhibits NTCP by reducing cholesterol absorption. As an NPC1L1 inhibitor, it modulates the bile acid pool, leading to decreased NTCP activation. This cholesterol-lowering agent showcases a novel approach to NTCP modulation with potential implications for hepatic functions. | ||||||
Bosentan | 147536-97-8 | sc-210957 | 10 mg | $195.00 | 3 | |
Bosentan indirectly inhibits NTCP by modulating the endothelin signaling pathway. As an endothelin receptor antagonist, it influences bile acid homeostasis, potentially impacting NTCP activity. This dual endothelin receptor blocker demonstrates a unique avenue for NTCP regulation beyond traditional hepatocellular pathways. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin indirectly inhibits NTCP by lowering cholesterol levels. As a potent HMG-CoA reductase inhibitor, it reduces bile acid synthesis, impacting NTCP activation. This statin exemplifies the intricate connections between cholesterol metabolism and NTCP regulation, suggesting potential implications for hepatic health. | ||||||
Irbesartan | 138402-11-6 | sc-218603 sc-218603A | 10 mg 50 mg | $106.00 $303.00 | 3 | |
Irbesartan indirectly inhibits NTCP through modulation of the renin-angiotensin-aldosterone system. As an angiotensin II receptor antagonist, it influences bile acid synthesis and NTCP expression. This antihypertensive agent unveils a potential link between cardiovascular regulation and hepatocellular transport mechanisms. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
Pravastatin indirectly inhibits NTCP by reducing cholesterol levels. As an HMG-CoA reductase inhibitor, it modulates bile acid synthesis, impacting NTCP activation. This statin sheds light on the intricate connections between cholesterol metabolism and NTCP regulation, suggesting potential implications for hepatic health. | ||||||
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $72.00 $94.00 | 8 | |
Telmisartan indirectly inhibits NTCP through modulation of the renin-angiotensin-aldosterone system. As an angiotensin II receptor antagonist, it influences bile acid synthesis and NTCP expression. This antihypertensive agent reveals a potential link between cardiovascular regulation and hepatocellular transport mechanisms. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil indirectly inhibits NTCP by reducing cholesterol levels. As a fibrate, it modulates bile acid synthesis, impacting NTCP activation. This lipid-lowering agent offers insights into the intricate connections between lipid metabolism and NTCP regulation, suggesting potential implications for hepatic health. | ||||||
Naringenin | 480-41-1 | sc-219338 | 25 g | $245.00 | 11 | |
Naringenin indirectly inhibits NTCP by suppressing bile acid synthesis. As a flavonoid, it modulates the expression of bile acid transporters, including NTCP. This natural compound presents a unique avenue for NTCP modulation, suggesting potential dietary influences on hepatocellular transport processes. | ||||||